Abstract:Propose: Instant blood-mediated inflammatory reaction (IBMIR) causes significant peri-transplant islet damage following intraportal transplantation. IBMIR is initiated and perpetuated by a cascade of cellular and soluble innate immune responses, including high-mobility group box 1, tissue factor, macrophage chemoattractant protein-1, and interleukin-1β. Thrombomodulin (TM) regulates coagulation and suppresses inflammatory functions of neutrophils and macrophages while CD47 inhibits phagocytosis by macrophages, reducing inflammation and tissue damage. The main objective of this study was to exploit the immunomodulatory efficacy of these two molecules to mitigate IBMIR. Method: Pancreatic islets were biotinylated, followed by transient and positional display on their surface novel forms of TM (SA-TM) and CD47 (SA-CD47) chimeric with a modified form of streptavidin by taking the advantage of strong affinity between biotin and streptavidin. The viability and function of the engineered islets as well as their ability to mitigate IBMIR were assessed. Co-engineered islets were transplanted intraportally into streptozotocin diabetic syngeneic recipients (150 IEQ/mouse). Unmodified islets or islets engineered with SA-TM served as control. Blood glucose levels were monitored and graft function was assessed using an intraperitoneal glucose tolerance test. Flow cytometry and transcriptomic analysis were conducted on graft recipients at different times post-transplantation. Results: Islets were successfully engineered with SA-TM/SA-CD47 combination without affecting their viability and function. SA-TM/SA-CD47 on rat splenocytes inhibited phagocytosis by mouse macrophages in vitro. Similarly, bone marrow cells engineered with SA-TM/SA-CD47 were resistant to clearance in allogeneic hosts. In an ex vivo blood loop assay, SA-TM/SA-CD47 prevented islet damage associated with the down-regulation of various inflammatory mediators driving IBMIR. In a syngeneic minimal mass model of intraportal islet transplantation, SA-TM/SA-CD47-engineered islets had enhanced engraftment as compared with SA-TM-engineered islets or unmodified islets. The enhanced engraftment was associated with a significant decrease in intragraft proinflammatory cells and transcritps involved in IBMIR. Conclusion: Engineering islets to codisplay on their surface SA-TM and SA-CD47 molecules as regulators of innate immune responses effectively inhibits peri-transplant islet graft loss with implications for both autologous and allogeneic islet transplantation. Funded in parts by NIH R01AI121281 award.

A metabolic role for CD47 in pancreatic β cell insulin secretion and islet transplant outcomes

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Successful Β Cells Islet Regeneration Instreptozotocin-Induced Diabetic Baboons Usingultrasound-Targeted Microbubble Gene Therapywith Cyclind2/cdk4/glp1

Advances in Anti-metabolic Disease Treatments Targeting CD47

CD47 Decline in Pancreatic Islet Cells Promotes Macrophage-Mediated Phagocytosis in Type I Diabetes

Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47

Targeted Pharmacological Therapy Restores Beta-Cell Function For Diabetes Remission

CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes

Cell autonomous functions of CD47 in regulating cellular plasticity and metabolic plasticity

Thrombospondin-1, CD47, and SIRPα display cell-specific molecular signatures in human islets and pancreata

201.1: Co-engineering Pancreatic Islets with Novel Forms of Thrombomodulin and CD47 As an Effective Means of Mitigating Instant Blood-Mediated Inflammatory Reaction

BENCH TO BEDSIDE: NOVEL MECHANISMS IN DIABETES AND METABOLISM Cornus Officinalis Induction of Pancreatic β-cell Autophagy as Revealed by Increased LC3 Expression and P62 Phosphorylation

Engineering Pancreatic Islets to Transiently Codisplay on Their Surface Thrombomodulin and CD47 Immunomodulatory Proteins as a Means of Mitigating Instant Blood-Mediated Inflammatory Reaction following Intraportal Transplantation

CD47: Beyond an immune checkpoint in cancer treatment

Is CD47 a potentially promising therapeutic target in cardiovascular diseases? - Role of CD47 in cardiovascular diseases

CD47 as a promising therapeutic target in oncology

Potential Protection Against Type 2 Diabetes in Obesity Through Lower CD36 Expression and Improved Exocytosis in β-Cells

Metabolic and functional specialisations of the pancreatic beta cell: gene disallowance, mitochondrial metabolism and intercellular connectivity

Pancreatic Islet Cell Therapy for Type I Diabetes: Understanding the Effects of Glucose Stimulation on Islets in Order to Produce Better Islets for Transplantation

Targeting the pancreatic β-cell to treat diabetes